We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Biochemistry
-
1. New-to-nature biocompatible lossen rearrangement in E. coli for industry use- Prof. Stephen Wallace
-
2. De novo designed proteins: a breakthrough in snakebite treatment
- Dr. Susana Vazquez Torres
- Cancer/Oncology
-
7. From lab to clinic: bridging cancer genetics and public health
- Prof. Clare Turnbull
-
8. Engineered yeast: a breakthrough in targeted cancer therapies
- Prof. Gautam Dantas
-
10. Cancer vaccines
- Dr. Elias Sayour
-
11. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
13. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
14. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
- Immunology & Inflammation
-
15. Macrophage-specific therapy and the lung’s mechanosensitive immune response
- Prof. Jahar Bhattacharya
-
16. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
17. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
19. Transmembrane domains and the regulation of trogocytosis in T cells
- Dr. Stefano Barbera
- Infectious Diseases/Microbiology
-
21. Lariocidin: a novel antibiotic that disrupts bacterial protein synthesis
- Prof. Gerry Wright
-
22. Kalihinol analog MED6-189: a promising pan-antimalarial candidate
- Prof. Karine Le Roch
-
23. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
25. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Methods
-
28. How big data and genomics are personalizing your health
- Prof. Michael Snyder
-
29. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
30. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
31. MassBank development and future
- Dr. Emma L. Schymanski
-
32. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
33. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
- Neurology/Neuroscience
-
34. Peptide-based eye drops for retinal degeneration: targeting photoreceptor survival with H105A- Dr. S. Patricia Becerra
-
35. Cloaked stem cell grafts: engineering immune-evasive neural transplants for Parkinson's therapy- Prof. Clare L. Parish
-
36. The case of an asymptomatic Alzheimer’s mutation carrier
- Dr. Jorge J. Llibre-Guerra
-
38. Rethinking the amyloid dogma in Alzheimer’s disease
- Prof. George Perry
-
39. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
40. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
41. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
42. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
43. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
44. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
45. Muscarinic acetylcholine receptor modulation in neurological diseases
- Prof. Andrew B. Tobin
- Pharmaceutical Sciences
-
46. Complex in vitro models and the future of drug safety and efficacy assessment
- Dr. Nadine Stokar-Regenscheit
-
47. Unlocking a cryptic pocket: a new approach to safer pain relief
- Prof. Susruta Majumdar
- Dr. Vipin Ashok Rangari
-
48. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
49. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
51. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
52. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
53. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
54. The regulation of cell therapy
- Prof. Moutih Rafei
-
55. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
56. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
58. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
59. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
Topics Covered
- Endometrial cancer immunotherapy
- Immune biomarkers
- Nivolumab
- Cabozantinib
- Tumour microenvironment
- Macrophages
- Personalised cancer treatment
- Immunotherapy resistance
Biography
Dr. Sacha Gnjatic is Professor of Oncological Sciences, Medicine, and Pathology at the Icahn School of Medicine at Mount Sinai, New York, and Associate Director of the Human Immune Monitoring Center. He received his PhD in Immunology from the University of Paris VII and completed postdoctoral research at Memorial Sloan Kettering Cancer Center. His research focuses on human immune responses to cancer, cancer immunotherapy, immune monitoring, and the identification of biomarkers and therapeutic targets. He has contributed to the immunological basis of cancer vaccines and immunotherapies in over 100 clinical trials and has authored more than 215 peer-reviewed publications and 10 patents.
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Gnjatic, S. (2026, October 29). Immunological biomarkers in cabozantinib and nivolumab treatment for endometrial cancer [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 2, 2026, from https://doi.org/10.69645/SHPA2660.Export Citation (RIS)
Publication History
- Published on October 29, 2026
Financial Disclosures
- Prof. Sacha Gnjatic has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
Immunological biomarkers in cabozantinib and nivolumab treatment for endometrial cancer
Published on October 29, 2026
19 min
A selection of talks on Oncology
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: We're joined
today by Dr. Sacha Gnjatic,
a professor at the Icahn School
of Medicine at Mount Sinai,
and a co-director of
the Human Immune
Monitoring Center there.
Dr. Gnjatic recently published
an important study on
immune biomarkers
in patients with
recurrent endometrial cancer
undergoing immunotherapy.
Dr. Gnjatic, thank you very
much for joining us today.
Prof. Gnjatic: Thank
you, Eyal, for having me.
Interviewer: Can you
start by providing
some background
regarding the gap that
you sought to address
in your research,
and what were your key findings?
Prof. Gnjatic: So we've been
interested in understanding
how immunotherapies work,
because as you know,
immunotherapies are now becoming
the mainstay of
cancer treatment,
but still, it's only usually
a minority of patients who
benefit from treatment.
Because immunotherapies work by
modulating the immune system,
we believe that we
should really understand
more about how immune cells
interact with tumors,
because most biomarkers so far
that define whether
a patient should
undergo immunotherapy
or not are based on
tumor markers rather
than immune markers.
I've been part of a
network called CIMAC,
which stands for Cancer Immune
Monitoring and Analysis Center,
which is funded by a
Moonshot from the NIH,
the National Cancer Institute.
The goal of that network
is to put four
institutions together,
of which I am the principal
investigator for Mount Sinai,
but we collaborate
with Dana-Farber,
with MD Anderson and Stanford,
and we're basically interested
in getting specimens
from patients who undergo
these immunotherapies,
and we're matched with trials
from the NCI umbrella,